Market Overview: Frontier Pharma-Rheumatoid Arthritis:Identifying And Commercializing First-In-Class Innovation : Now at

Posted by Abhishek Budholiya on 10:17 PM with No comments
"Outskirts Pharma: Rheumatoid Arthritis Identifying and Commercializing First-in-Class Innovation". This profoundly focused market is immersed with various focused on monoclonal Antibody (mab) helps and little particles, yet a greater amount of these medicines are relied upon to enter the market throughout the following not many years. Notwithstanding this, the present developmental pipeline is quite inventive past these me-excessively items and incremental advancements and guarantees various first-in-class items over all stage.

Browse Full Report with TOC:

The market is likewise portrayed by high movement in permitting and co-advancement arrangements. Specifically, there is maintained business investment in pipeline biologic helps with a go of atomic targets. There is likewise significant investment in little atom inhibitors of intracellular kinases notwithstanding their clinical exhibitions not being too secured as biologics or mabs.


  • The report analyzes the RA pipeline and strategic alliance landscape with particular emphasis on first-in-class programs.
  • A brief introduction to RA, including symptoms, pathophysiology, and an overview of the pharmacotherapy
  • Highlights of the changing molecular target landscape between marketed and pipeline products with particular focus on innovation


Reasons to buy

  • The report will assist business development strategies of companies who wish to develop RA therapies with improved benefits to existing treatments. In addition, this report will be of interest to companies seeking to expand pipeline portfolios through licensing agreements and co-development deals allowing them to 
  • Understand the overall focal shifts in therapeutic molecular targets of RA treatments

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7

2 Introduction 8
2.1 The Case for Innovation 8
2.1.1 Growing Opportunities for Biologic Products 8
2.1.2 Diversification of Molecular Targets 8

3 Clinical and Commercial Landscape 11
3.1 Disease Overview 11
3.1.1 Disease Symptoms 12
3.1.2 Environmental Factors and Genetic Predisposition 12

4 Assessment of Pipeline Product Innovation 23
4.1 Rheumatoid Arthritis Pipeline by Molecule Type, Phase and Therapeutic Targets 23
4.2 Frequently Targeted Intracellular Kinases 25

 First-in-Class Target and Pipeline Program Evaluation 37
5.1 Cytokines and Receptors 37
5.1.1 Pipeline Programs which Target HMGB-1 37
5.1.2 Pipeline Programs which Target IL-10 Receptor 42

6 Deals and Strategic Consolidations 73
6.1 Licensing Deals 73
6.2 Co-development Deals 86
6.3 First-in-Class Programs which have not been involved in Licensing or Co-Development Deals 98

7 Appendix 99
7.1 Abbreviations 99
7.2 Methodology 102
7.3 References 102

About Us is the most comprehensive collection of market research reports. services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: +1-866-997-4948